Overview

Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC

Status:
Not yet recruiting

Trial end date:
2023-11-30

Target enrollment:

Participant gender:

Summary

This is a phase II, multicenter, single-arm, non-blind study. To 21 patients with PD-L1 ≥50% locally advanced non-small cell lung cancer, the combination of Pembrolizumab and platinum-doublets will be intravenously administered without radiotherapy to evaluate the efficacy and safety of combination therapy with Pembrolizumab and platinum-doublets.

Phase:

Phase 2

Details

Lead Sponsor:

Kobe Minimally Invasive Cancer Center

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Cisplatin
Paclitaxel
Pembrolizumab
Pemetrexed